DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CEFUROXIME AXETIL
Clinical Trials for Cefuroxime Axetil
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00000752 | Preventing Frequent Sinus Infections in HIV-Infected Patients | Withdrawn | Adams Laboratories | Phase 2 | To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted. |
NCT00000752 | Preventing Frequent Sinus Infections in HIV-Infected Patients | Withdrawn | Glaxo Wellcome | Phase 2 | To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted. |
NCT00000752 | Preventing Frequent Sinus Infections in HIV-Infected Patients | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted. |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Cefuroxime Axetil
Condition Name
Condition MeSH
Clinical Trial Locations for Cefuroxime Axetil
Trials by Country
Clinical Trial Progress for Cefuroxime Axetil
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Cefuroxime Axetil
Sponsor Name